tiprankstipranks
Pascal Biosciences Inc (TSE:NEVI)
CNQX:NEVI

Pascal Biosciences Inc (NEVI) Stock Price & Analysis

3 Followers

NEVI Stock Chart & Stats

Day’s RangeC$0 - C$0
52-Week RangeC$0.02 - C$0.20
Previous CloseC$0.14
Volume331.00K
Average Volume (3M)34.23K
Market Cap
C$5.34M
Enterprise ValueC$5.44M
Total Cash (Recent Filing)C$575.14K
Total Debt (Recent Filing)C$670.51K
Price to Earnings (P/E)-10.3
Beta0.35
Jul 25, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding38,140,327
10 Day Avg. Volume58,528
30 Day Avg. Volume34,231
Standard Deviation0.41
R-Squared0.00757
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)-95.26
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

45.05%0.00%0.00%54.95%
45.05% Insiders
0.00% Other Institutional Investors
54.95% Public Companies and
Individual Investors

NEVI FAQ

What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was C$0.01 and its highest was C$0.20 in the past 12 months.
    What is Pascal Biosciences Inc’s market cap?
    Currently, no data Available
    When is Pascal Biosciences Inc’s upcoming earnings report date?
    Pascal Biosciences Inc’s upcoming earnings report date is Jul 25, 2024 which is in 67 days.
      How were Pascal Biosciences Inc’s earnings last quarter?
      Currently, no data Available
      Is Pascal Biosciences Inc overvalued?
      According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Pascal Biosciences Inc pay dividends?
        Pascal Biosciences Inc does not currently pay dividends.
        What is Pascal Biosciences Inc’s EPS estimate?
        Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Pascal Biosciences Inc have?
        Pascal Biosciences Inc has 38,140,327 shares outstanding.
          What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Pascal Biosciences Inc?
          Currently, no hedge funds are holding shares in TSE:NEVI
          ---

          Pascal Biosciences Inc Stock Smart Score

          N/A
          Not Ranked
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Positive
          20 days / 200 days
          Momentum
          833.33%
          12-Months-Change

          Fundamentals

          Return on Equity
          -355.00%
          Trailing 12-Months
          Asset Growth
          8877.46%
          Trailing 12-Months

          Company Description

          Pascal Biosciences Inc

          Pascal Biosciences Inc is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The company has one operating segment, biotechnology research and development with lab and computer equipment in the United States of America.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Reliq Health Technologies
          Helix BioPharma
          Medmira
          Biocure Technology Inc
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis